Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors.
about
Autophagy in plasma cell pathophysiologyMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTrial Watch: Proteasomal inhibitors for anticancer therapyMCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBMolecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-XElucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome.Subunit specific inhibitors of proteasomes and their potential for immunomodulationA plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cellsParadoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Discovery of an Inhibitor of the Proteasome Subunit Rpn11.Development of proteasome inhibitors as research tools and cancer drugsTranslating DRiPs: MHC class I immunosurveillance of pathogens and tumors.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins.Editorial: Proteostenosis: cancer's Achilles heel?Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.Proteasome inhibitors in cancer therapy.
P2860
Q27015920-32B6F82D-44B9-4F89-A07C-05BCFAEED3F2Q28082335-77D569A5-60CA-41CF-B770-0158A8B98F25Q28082910-13509AB2-57C5-4862-8952-D94DE4EEA04BQ34038263-1054A472-C318-4E5F-8E25-E6FED357BDDDQ34608271-31C684B0-BDF4-497F-BE1E-D3E35EE4F90AQ35024457-6E6E23DC-33EB-4D91-A69D-7051D480CE74Q35408665-30D45F3A-F23F-401D-83D9-E77ED3293E03Q35494324-1671F195-D635-4EDB-A76A-342E5D23886AQ35555565-F01438DD-9F69-40B2-89BF-BEEE472B3012Q36002378-C710B251-A7EF-4CC8-AF18-B372496CF8FBQ36042649-037FF17C-C725-4993-99DC-D61B71BFCDD1Q36111590-9EA3D6B8-B9D3-43E9-8A2D-187AC443F54AQ36150369-0479D088-B88F-4A9B-89E4-19B5453400F6Q36278259-45B6C8C5-80FD-4224-A22E-471680CD71C2Q36389262-245FF87A-1F0A-4998-AF38-0044F6F9E2AAQ37644973-F2E870D0-6660-40F8-87B0-D226B1ACB06EQ38258197-D2BABB8B-3D36-467C-B697-6481FDBCF036Q39463298-64DD52E2-E81B-459D-A7BF-7D6AFD0BF580Q42413559-7DC8BDE3-1C1F-46EE-8416-BA86FDC53D97Q43806219-185AD349-61AC-4F6B-95E8-2FA554A033D6Q47096168-D55A17C9-E8A9-49CC-831C-96090AA19D06Q53752929-D124B4F7-4B0E-4E95-A19D-164A0AEAF470
P2860
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@en
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@nl
type
label
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@en
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@nl
prefLabel
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@en
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@nl
P2093
P2860
P50
P356
P1476
Pivotal Advance: Protein synth ...... ells to proteasome inhibitors.
@en
P2093
Alexandre Mezghrani
Elena Pasqualetto
Fulvia Cerruti
Giada Bianchi
Laura Oliva
Mary Raule
Paolo Cascio
P2860
P304
P356
10.1189/JLB.1011497
P577
2012-06-08T00:00:00Z